Barry McKernan talks about portfolio risk management techniques and how Pfizer have been using a new method of Value at Risk analysis which has been customised to monitor risks and exposures more accurately than its past approach. Pfizer is one of the world’s largest pharmaceutical companies by revenues. Headquartered in New York, the company contains a healthcare portfolio which includes medicines, vaccines and many of the world’s best-known consumer healthcare products.
Pfizer has a cash portfolio of approximately $46 billion, which is comprised of various instruments, ranging from long- and short-term debt securities to investment grade corporate bonds. With a small team, maintaining surveillance of credit risk in a portfolio of this scale requires innovative techniques and technology.
This webinar was held in Wednesday 10th September 2014.